Quintiles Transnational Holdings Inc., through its subsidiary, Quintiles Transnational Corp., provides biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the Asia-Pacific. The company’s Product Development segment offers project management and clinical monitoring services, including study design and operational planning, investigator/site recruitment, site and regulatory start up, patient recruitment, clinical monitoring, project management for conducting various multi-site trials, and late phase interventional services; and clinical trial support services comprising clinical data management, biostatistical, cardiac safety and ECG laboratory, safety and pharmacovigilance, and phase I clinical pharmacology services, as well as clinical trial, genomic, and bioanalytical laboratory services. This segment also provides strategic planning and design services for biomarkers, genomics, and personalized medicine, as well as offers model-based drug development and regulatory affairs services; and consulting services, such as product development strategy, regulatory and compliance, and process and IT implementation consulting services. Its Integrated Healthcare Services segment offers commercial services comprising contract sales, market entry/market exit, integrated channel management, patient engagement, and market access and commercialization consulting services; real-world late phase research services, such as observational studies, comparative effectiveness studies, and product and disease registry services; and communication and health engagement services, including digital patient, and brand and scientific communications services. The segment also provides payer and provider solutions, and advisory services. The company serves biopharmaceutical companies, including medical device and diagnostics companies. Quintiles Transnational Holdings Inc. was founded in 1982 and is based in Durham, North Carolina.